Radiotherapy can be a Cofactor in the Development and Severity of Lapatinib-Capecitabine-Related Skin Rash
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Bilimsel Tip Yayinevi
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Skin rash induced by concurrent radiotherapy during lapatinib-capecitabine (LC) treatment has been rarely reported. We aim to draw attention to the potential of radiotherapy to act as a cofactor in the development of LC-related skin rash.Herein, we report a case with a drug-related skin rash triggered by radiotherapy during LC treatment.A 31-year-old woman with inflammatory metastatic breast cancer presented with a skin rash during LC treatment combined with radiotherapy. She was started on LC treatment, and palliative whole cranial radiotherapy was applied 3 days later. Three days after the radiotherapy, acneiform lesions started from the scalp and a maculopapular rash developed on the trunk and extremities. LC treatment was interrupted and skin lesions regressed rapidly with topical dermatological care, oral H1-antihistamine, and short-term oral steroid treatment. Although LC treatment was restarted alone in the follow-up, no recurrence was observed.Radiotherapy may be a cofactor in the development and severity of skin toxicity during LC treatment. There is a need to elucidate whether the immunological mechanisms of skin eruptions occurring during concomitant chemoradiotherapy are due to the radiosensitizing effects of biological agents or exacerbation by radiotherapy.
Açıklama
Anahtar Kelimeler
Lapatinib, capecitabine, radiotherapy, skin rash, drug allergy, Management, Toxicity
Kaynak
Astim Allerji Immunoloji
WoS Q Değeri
Q4
